Erythropoietin
- Generic Name
- Erythropoietin
- Brand Names
- Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11096-26-7
- Unique Ingredient Identifier
- 64FS3BFH5W
- Background
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...
- Indication
用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。
- Associated Conditions
- Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine
- Associated Therapies
- -
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT00776425
A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 281
- Registration Number
- NCT00773331
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2825
- Registration Number
- NCT00773513
- Locations
- 🇦🇺
Gosford Hospital; Renal, Gosford, New South Wales, Australia
🇭🇷General Hospital Josip Bencevic; Department of Haemodialysis, Slavonski Brod, Croatia
🇦🇺Renal Research Dr Simon Roger, Gosford, New South Wales, Australia
Neonatal Erythropoietin in Asphyxiated Term Newborns
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 24
- Registration Number
- NCT00719407
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
- Conditions
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 421
- Registration Number
- NCT00717821
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 337
- Registration Number
- NCT00701714
- Locations
- 🇦🇹
Diakonissen KH Salzburg, Salzburg, Austria
🇦🇹LKH Steyr, Steyr, Austria
🇦🇹Krankenanstalt der Stadt Wien, Wien, Austria
Randomized Trial of Erythropoietin During Cerebral Malaria
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2008-06-13
- Lead Sponsor
- Claude Bernard University
- Target Recruit Count
- 120
- Registration Number
- NCT00697164
- Locations
- 🇲🇱
Gabriel Toure Hospital, Bamako, Mali
Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2008-05-30
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT00687518
- Locations
- 🇫🇷
Unité d'Investigation Clinique - Centre d'Investigation Clinique - Hôpital de Pontchaillou, Rennes, France
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
- Conditions
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00656448
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 160
- Registration Number
- NCT00628043
- Locations
- 🇯🇵
Chugoku/Shikoku Region, Chugoku/Shikoku, Japan
🇯🇵Chubu Region, Chubu, Japan
🇯🇵Kyushu Region, Kyushu, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.